Dr. Yongliang Fang obtained his Ph.D. from Dartmouth College. His main research interests include protein engineering, immunogenicity analysis, protein deimmunization, drug discovery, and clinical translation. As a co-founder and Chief Operating Officer of Occulo Holdings, LLC, he led Occulo's Series A financing, pipeline development, in-licensing of key assets, and out-licensing of preclinical programs. Currently, he serves as the Chief Operating Officer of Zhejiang Doer Biologics Co., Ltd., where he is primarily responsible for regulatory affairs, clinical translation and operations, and business development for Doer Bio's innovative biotherapeutics.